Get the Stockscreener App
21.81
3.79%
-0.86
After Hours:
20.18
-1.63
-7.47%
Centessa Pharmaceuticals Plc Adr stock is traded at $21.81, with a volume of 1.30M.
It is down -3.79% in the last 24 hours and up +27.47% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$22.67
Open:
$22.49
24h Volume:
1.30M
Relative Volume:
1.13
Market Cap:
$2.92B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-13.98
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
+38.65%
1M Performance:
+27.47%
6M Performance:
+27.84%
1Y Performance:
+44.44%
1-Day Range:
$21.47
$22.84
1-Week Range:
$15.83
$23.24
52-Week Range:
$9.60
$23.24
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
21.81 | 3.04B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Aug-29-25 | Resumed | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Fred Alger Management LLC Cuts Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharma chief technology officer sells $1m in shares - Investing.com
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 1-Year HighHere's What Happened - MarketBeat
What is Lifesci Capital's Forecast for CNTA Q3 Earnings? - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap UpHere's What Happened - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 19.1 USD By Investing.com - Investing.com Australia
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Acquired by Cutter Capital Management LP - MarketBeat
Cormorant Asset Management LP Lowers Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 19.1 USD - Investing.com
Alibaba, Palantir Lead Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Alibaba, Palantir Lead Market Cap Stock Movers on Monday - Investing.com
Palantir, EchoStar lead market cap stock movers on Monday By Investing.com - Investing.com Nigeria
Palantir, EchoStar lead market cap stock movers on Monday - Investing.com India
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 9.1%Here's What Happened - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA is First Light Asset Management LLC's 3rd Largest Position - MarketBeat
Nantahala Capital Management LLC Increases Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
What is Lifesci Capital’s Forecast for CNTA Q3 Earnings? - Defense World
Armistice Capital LLC Makes New $6.73 Million Investment in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Driehaus Capital Management LLC Sells 502,650 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Siren L.L.C. Has $42.57 Million Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Wellington Management Group LLP Has $2 Million Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
HighTower Advisors LLC Raises Holdings in Onto Innovation Inc. $ONTO - Defense World
American Century Companies Inc. Increases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
American Century Companies Inc. Buys 83,678 Shares of AdvanSix $ASIX - Defense World
Microsoft Corporation $MSFT Shares Bought by SilverOak Wealth Management LLC - Defense World
American Century Companies Inc. Increases Position in Mizuho Financial Group, Inc. $MFG - Defense World
Vanguard Group Inc. Has $59.77 Million Holdings in Sturm, Ruger & Company, Inc. $RGR - Defense World
Russell Investments Group Ltd. Invests $3.27 Million in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - Defense World
FY2025 Earnings Estimate for CNTA Issued By Chardan Capital - Defense World
Equities Analysts Issue Forecasts for CNTA FY2025 Earnings - Defense World
Centessa Pharma general counsel sells $103k in shares By Investing.com - Investing.com South Africa
Centessa Pharma general counsel sells $103k in shares - Investing.com India
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - Placera.se
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - GlobeNewswire Inc.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bank of New York Mellon Corp Buys Shares of 10,257 Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA): On Track To A Higher Share Price - stocksregister.com
The Future of Centessa Pharmaceuticals plc ADR: Analyzing CNTA - investchronicle.com
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares By Investing.com - Investing.com India
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares - Investing.com
Cerity Partners LLC Invests $471,000 in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR Inc. (CNTA) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Taseko Mines Ltd: Navigating Market Fluctuations with a 1.09B Market Cap - investchronicle.com
Codere Online Luxembourg (NASDAQ:CDRO) & Take-Two Interactive Software (NASDAQ:TTWO) Critical Analysis - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Buy” by Analysts - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% After Insider Selling - Defense World
Centessa Pharmaceuticals’ Accardi sells $210,000 in shares - Investing.com
Centessa Pharma CEO Saha sells $694,826 in shares - Investing.com
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):